Evidence map›Paper›PMID 42272168›Full record

ReviewPharmacotherapy2026

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Jonathan H Ryder, Shawnalyn W Sunagawa, Nathaniel J Rhodes, Trevor C Van Schooneveld, Jeremy E Tigh, Sean N Avedissian, Nicolas Cortes-Penfield

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jonathan H RyderDepartment of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0003-4566-1905
Shawnalyn W SunagawaDepartment of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0009-0005-3068-3732
Nathaniel J RhodesDepartment of Pharmacy Practice, Midwestern University, Downers Grove, Illinois, USA.ORCID 0000-0002-0018-5434
Trevor C Van SchooneveldDepartment of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0002-9928-4546
Jeremy E TighDepartment of Pharmacy, Good Samaritan Regional Medical Center, Corvallis, Oregon, USA.ORCID 0000-0003-0018-7963
Sean N AvedissianDepartment of Pharmacy Practice and Science, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0002-0935-6455
Nicolas Cortes-PenfieldDepartment of Internal Medicine, Division of Infectious Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA.ORCID 0000-0002-6302-9471

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optimal cephalexin and cefadroxil dosing for skin and soft tissue infections (SSTIs) is unclear. We summarize clinical and pharmacokinetic/pharmacodynamic (PK/PD) data that compare dosing strategies for SSTIs. Additionally, we conduct population PK target attainment simulations for varying doses of cephalexin and cefadroxil for Staphylococcus aureus and Group A Streptococcus. Although some clinical data support lower doses in mild SSTIs, higher doses optimize PK/PD parameters in moderate-severe SSTIs, especially due to Staphylococcus aureus. Further prospective clinical and PK/PD studies, especially in obese adults, would be beneficial.

Indexed as

First Generation CephalosporinsSkin Diseases, BacterialSoft Tissue InfectionsCefadroxilCephalexinDose-Response Relationship, DrugHumansStaphylococcal InfectionsStaphylococcus aureusCefadroxilCephalexinFirst Generation Cephalosporinscefadroxilcephalexinfirst‐generation cephalosporinspharmacokineticsskin and soft tissue infection

Identifiers

PMID42272168
PMCPMC13254493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.